Abnormal Upregulation of Cardiovascular Disease Biomarker PLA2G7 Induced by Proinflammatory Macrophages in COVID-19 patients
Yang LI, Yongzhong JIANG, Yi ZHANG, Naizhe LI, Qiangling YIN, Linlin LIU, Xin LV, Yan LIU, Aqian LI, Bin FANG, Jiajia LI, Hengping YE, Gang YANG, Xiaoxian CUI, Yang LIU, Yuanyuan QU, Chuan LI, Jiandong LI, Dexin LI, Shiwen WANG, Zhongtao GAI, Faxian ZHAN, Mifang LIANG
Received date: 30th September 2020
Coronavirus disease 2019 (COVID-19) triggers distinct patterns of pneumonia progression with multiorgan disease, suggesting immune-mediated as opposed to pathogen-mediated organ inflammation contributed to severity in COVID-19 patients, calling for cell- and/or tissue-type specific host injury markers. As partial cytokine blood RNA level was not correlated with protein levels in blood, we performed an integrated hypothesis-free single biomarker analysis framework on nasal swabs (n=484) from patients with COVID-19 in GSE152075 and identified phospholipase A2 group VII (PLA2G7) as a candidate biomarker in COVID-19. Moreover, PLA2G7 was predominantly expressed by proinflammatory macrophages in lungs emerging with progression of COVID-19. More than 500 clinical samples, including nasal swabs and serum samples, were collected. RNA level of PLA2G7 was identified in nasal swabs from both COVID-19 and pneumonia patients, other than health individuals. Serum protein levels of PLA2G7 were found to be elevated and beyond the normal limit in COVID-19 patients. Conclusively, we identified and validated PLA2G7 was abnormally enhanced in COVID-19 patients at both nucletide and protein aspects. Additionally, PLA2G7 might play an import role in impaired type I interferon activity and the prevalence of cardiovascular involvements seen in COVID-19 patients. PLA2G7 could be a potential prognostic and therapeutic target in COVID-19.
This is an abstract of a preprint hosted on a preprint server, which is currently undergoing peer review at Scientific Reports. The findings have yet to be thoroughly evaluated, nor has a decision on ultimate publication been made. Therefore, the results reported should not be considered conclusive, and these findings should not be used to inform clinical practice, or public health policy, or be promoted as verified information.